Mar 31, 2023 by James HalleyWhy Shares of Atai Life Sciences Rose FridayThe company's co-founder and chairman increased his position and explained why.
Mar 31, 2023 by James HalleyWhy Shares of Brookdale Senior Living Jumped This WeekThe stock quickly bounced back from a 52-week low.
Mar 31, 2023 by James HalleyThese 2 Pot Stocks Are Up Big in 2023. Here's WhyScotts Miracle-Gro and TerrAscend have disciplined plans toward growth.
Mar 30, 2023 by James HalleyWhy Shares of Terns Pharmaceuticals Soared This WeekThe company is showing progress toward a NASH therapy.
Mar 30, 2023 by James HalleyWhy Shares of Viking Therapeutics Skyrocketed This WeekThe clinical-stage stock nearly doubled in price.
Mar 30, 2023 by James Halley2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy ItEditas Medicine is a high-risk stock with the potential of a big reward.
Mar 29, 2023 by James HalleyWhy Shares of Sharecare Slumped on WednesdayYearly and quarterly losses were greater than expected.
Mar 29, 2023 by James HalleyWhy Shares of ProQR Therapeutics Dropped on WednesdayThe clinical-stage biotech released fourth-quarter and full-year earnings.
Mar 29, 2023 by James Halley2 Reasons to Buy Aurora Cannabis and 1 Reason to Sell ItThis Canadian retailer saw growth in the last quarter sequentially and year over year.
Mar 28, 2023 by James HalleyWhy Shares of Harmony Bioscience Are Slumping TuesdayA short-seller report drove the stock's shares down.
Mar 28, 2023 by James HalleyWhy Intra-Cellular Therapies Climbed TuesdayThe company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression.
Mar 27, 2023 by James HalleyWhy Shares of Iovance Biotherapeutics Jumped MondayThe company filed a Biologics License Application to the FDA for its lead therapy.
Mar 27, 2023 by James HalleyWhy Shares of BioNTech Slumped MondayThe company released fourth-quarter earnings.
Mar 26, 2023 by James Halley3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term PotentialThese three spinoffs are already profitable.
Mar 25, 2023 by James Halley2 Clinical Research Stocks That Could Grow by More Than 10% This Year, and 1 to WatchThese companies strive to bring down the cost of developing new therapies.
Mar 24, 2023 by James HalleyWhy Shares of Orchestra BioMed Jumped This WeekThe company is considered one of the top medical device start-ups this year.
Mar 24, 2023 by James HalleyWhy Shares of Immuneering Jumped This WeekImmuneering is ready to share information regarding its lead therapy.
Mar 24, 2023 by James HalleyWhy Shares of 89bio Soared This WeekThe company released positive results for its lead therapy.
Mar 23, 2023 by James HalleyWhy Shares of Regeneron Are Rising ThursdayRegeneron released positive phase 3 trial results for its therapy Dupixent.
Mar 23, 2023 by James Halley3 Things About AbbVie That Smart Investors KnowThinking long-term could pay off now for AbbVie investors.
